Full-Service CRO & Consultancy for Oncology & Hematology
Advance your Novel Oncology Therapies to Approval and Commercial Success
When the complexities of designing and executing cancer trials in a highly competitive market can mean delays in delivering urgently needed treatments to patients, it pays to have a trusted partner by your side. In the past five years, our experienced teams have helped clients with more than 400 oncology and hematology studies and have worked on more than 30 US and European regulatory marketing applications.
Developing an oncology or hematology therapy? Let’s Talk.
Oncology/Hematology Experience in the Past 5 Years
Clinical Trials & Consulting Projects
Marketing Applications (NDAs, BLAs, MAAs) Prepared
of global operations team members have oncology/hematology experience
Clinical Trial & Regulatory Consulting Expertise for Cancers & Blood Disorders
Our expertise allows us to confidently handle the most complex trials and patient populations with the attention and focus needed to navigate the cancer and hematology landscape.
Whatever your challenges are, Veristat provides creative and strategic approaches to inform your decision-making, mitigate trial risks, prove safety and efficacy, and achieve approval success. Our regulatory and clinical development experts are poised to launch your oncology or hematology trial:
Scientific Excellence Across Cancer & Hematology Indications
- and more...
- Acute Myeloid Leukemia
- Hodgkin’s Lymphoma
- Multiple Myeloma
- and more...
Sickle Cell Anemia
- Wiskott-Aldrich Syndrome
Case Study: Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial
A clinical-stage biopharmaceutical company approached Veristat in a multi-center, randomized Phase II study of a modified synthetic peptide in patients with exocrine pancreatic cancer. The study aimed to establish the efficacy and safety of combinations of the therapy in patients with stage IV exocrine pancreatic cancer. Learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges, including slow recruitment, data cleansing post-MSU, and site staffing.
"By partnering with a like-minded, scientifically focused company such as Veristat, we have found a core team of high caliber collaborators who can help us to accelerate the development of our new class of targeted cancer therapies."